Cargando…
Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients
Hepatitis C virus infection (HCV), one of the greatest causes of liver disease, is a frequent complication in patients with end-stage renal disease (ESRD) on dialysis. ESRD is defined as decreased glomerular filtration and also accompanied by impaired function of the immune system. Galectin-3 is a β...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405569/ https://www.ncbi.nlm.nih.gov/pubmed/28487598 http://dx.doi.org/10.1155/2017/6275987 |
_version_ | 1783231795582468096 |
---|---|
author | Lukic, Ruzica Gajovic, Nevena Jovanovic, Ivan Jurisevic, Milena Mijailovic, Zeljko Maric, Veljko Popovska Jovicic, Biljana Arsenijevic, Nebojsa |
author_facet | Lukic, Ruzica Gajovic, Nevena Jovanovic, Ivan Jurisevic, Milena Mijailovic, Zeljko Maric, Veljko Popovska Jovicic, Biljana Arsenijevic, Nebojsa |
author_sort | Lukic, Ruzica |
collection | PubMed |
description | Hepatitis C virus infection (HCV), one of the greatest causes of liver disease, is a frequent complication in patients with end-stage renal disease (ESRD) on dialysis. ESRD is defined as decreased glomerular filtration and also accompanied by impaired function of the immune system. Galectin-3 is a β-galactoside-binding lectin, involved in various biological processes including pathogenesis of chronic renal disease. The aim of our study was to estimate disease severity in ESRD HCV(+) patients and analyze the serum concentrations of IL-1β, IL-4, IL-23, and IL-6; anti-HCV antibodies; and galectin-3. Also, we attempted to determine potential correlation between galectin-3 level and parameters of disease severity ALT and AST. Our results showed decreased levels of ALT and AST (p = 0.00), demonstrating less liver destruction in ESRD HCV(+) patients in comparison to HCV(+) patients. Increased levels of IL-6 (p = 0.03) implicate a hepatoprotective role of IL-6 in these patients. Also, level of galectin-3 (p = 0.00) in the serum of ESRD HCV(+) patients was higher than that of HCV(+) patients. This alteration was accompanied with negative correlation between galectin-3 and AST and ALT, respectively (p = 0.029; p = 0.033). The presence of increased systemic levels of IL-6 and Gal-3 in ESRD HCV(+) patients may be an attempt to counteract or limit ongoing proinflammatory processes and to downregulate chronic inflammation, suggesting the new aspects of HCV infection in ESRD patients. |
format | Online Article Text |
id | pubmed-5405569 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-54055692017-05-09 Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients Lukic, Ruzica Gajovic, Nevena Jovanovic, Ivan Jurisevic, Milena Mijailovic, Zeljko Maric, Veljko Popovska Jovicic, Biljana Arsenijevic, Nebojsa Dis Markers Research Article Hepatitis C virus infection (HCV), one of the greatest causes of liver disease, is a frequent complication in patients with end-stage renal disease (ESRD) on dialysis. ESRD is defined as decreased glomerular filtration and also accompanied by impaired function of the immune system. Galectin-3 is a β-galactoside-binding lectin, involved in various biological processes including pathogenesis of chronic renal disease. The aim of our study was to estimate disease severity in ESRD HCV(+) patients and analyze the serum concentrations of IL-1β, IL-4, IL-23, and IL-6; anti-HCV antibodies; and galectin-3. Also, we attempted to determine potential correlation between galectin-3 level and parameters of disease severity ALT and AST. Our results showed decreased levels of ALT and AST (p = 0.00), demonstrating less liver destruction in ESRD HCV(+) patients in comparison to HCV(+) patients. Increased levels of IL-6 (p = 0.03) implicate a hepatoprotective role of IL-6 in these patients. Also, level of galectin-3 (p = 0.00) in the serum of ESRD HCV(+) patients was higher than that of HCV(+) patients. This alteration was accompanied with negative correlation between galectin-3 and AST and ALT, respectively (p = 0.029; p = 0.033). The presence of increased systemic levels of IL-6 and Gal-3 in ESRD HCV(+) patients may be an attempt to counteract or limit ongoing proinflammatory processes and to downregulate chronic inflammation, suggesting the new aspects of HCV infection in ESRD patients. Hindawi 2017 2017-04-11 /pmc/articles/PMC5405569/ /pubmed/28487598 http://dx.doi.org/10.1155/2017/6275987 Text en Copyright © 2017 Ruzica Lukic et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Lukic, Ruzica Gajovic, Nevena Jovanovic, Ivan Jurisevic, Milena Mijailovic, Zeljko Maric, Veljko Popovska Jovicic, Biljana Arsenijevic, Nebojsa Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients |
title | Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients |
title_full | Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients |
title_fullStr | Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients |
title_full_unstemmed | Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients |
title_short | Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients |
title_sort | potential hepatoprotective role of galectin-3 during hcv infection in end-stage renal disease patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405569/ https://www.ncbi.nlm.nih.gov/pubmed/28487598 http://dx.doi.org/10.1155/2017/6275987 |
work_keys_str_mv | AT lukicruzica potentialhepatoprotectiveroleofgalectin3duringhcvinfectioninendstagerenaldiseasepatients AT gajovicnevena potentialhepatoprotectiveroleofgalectin3duringhcvinfectioninendstagerenaldiseasepatients AT jovanovicivan potentialhepatoprotectiveroleofgalectin3duringhcvinfectioninendstagerenaldiseasepatients AT jurisevicmilena potentialhepatoprotectiveroleofgalectin3duringhcvinfectioninendstagerenaldiseasepatients AT mijailoviczeljko potentialhepatoprotectiveroleofgalectin3duringhcvinfectioninendstagerenaldiseasepatients AT maricveljko potentialhepatoprotectiveroleofgalectin3duringhcvinfectioninendstagerenaldiseasepatients AT popovskajovicicbiljana potentialhepatoprotectiveroleofgalectin3duringhcvinfectioninendstagerenaldiseasepatients AT arsenijevicnebojsa potentialhepatoprotectiveroleofgalectin3duringhcvinfectioninendstagerenaldiseasepatients |